Log inSign up
Pharma-Marketing.comPharma-Marketing.com
  • Industry
  • Digital Health & AI
  • Channels
  • People
  • Agencies
  • Glossary
Log inSign up
  • Terms of Service
  • Privacy Policy
  • Cookie settings
  • Imprint
Pharma-Marketing.com


All rights reserved.

We use AI tools in the creation of certain content.

Pharma Marketing

Data-privacy settings

We use cookies to improve our website and services. They help us understand how visitors use our website. Some cookies are required for the website to function. These are marked as “essential” in the details.

AcceptEssential cookie
NameData-privacy settings
ProviderPharma-Marketing.com
PurposeStores these privacy settings in your browser.
Privacy policyPrivacy policy
Cookiespm_data_privacy
Cookie expiration180 days
Accept
NameGoogle Analytics
ProviderGoogle LLC
PurposeCookies by Google are used for website analytics. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_ga, _gat, _gid
Cookie expiration2 Years
Accept
NameGoogle Ads
ProviderGoogle LLC
PurposeCookies by Google Ads are used for advertising and targeting purpose.
Privacy policyPrivacy policy
Cookies__gsas, __gpi, __gpi_optout, NID, DSID, test_cookie, id, __gads
Cookie expiration2 Years
Accept
NameFacebook
ProviderFacebook Inc.
PurposeCookies by Facebook are used for advertising and marketing activities. Generates statistical data on how the visitor uses the website.
Privacy policyPrivacy policy
Cookies_fbp, fr
Cookie expiration2 Years
Accept
NameMicrosoft Clarity
ProviderMicrosoft Corporation
PurposeCookies by Microsoft Clarity are used for website analytics, heatmaps, and session recordings. They help us understand how visitors interact with our website so we can improve usability and performance.
Privacy policyPrivacy policy
Cookies_clck, _clsk, CLID, ANONCHK, MR, MUID, SM
Cookie expirationUp to 1 Year

Rote-Hand-Brief – Direct Safety Communication to Healthcare Professionals

Contents

  1. What is a Rote-Hand-Brief?
  2. How does it differ from other information?
  3. Which information matters most?
  4. What should companies consider when providing it?
  5. Conclusion: Prioritize clear safety information and implementation

What is a Rote-Hand-Brief?

A Rote-Hand-Brief informs healthcare professionals about important new medicine-safety findings and necessary actions in Germany. Pharmaceutical companies distribute it in agreement with the responsible authorities. The corresponding international term is Direct Healthcare Professional Communication (DHPC).

The red hand is a recognizable signal for safety information. A letter may address new contraindications, necessary monitoring or changes to use. Not every product update or adverse-reaction report is a Rote-Hand-Brief.

How does it differ from other information?

The summary of product characteristics and package leaflet describe approved conditions of use. A DHPC draws attention to a significant safety change and its practical implications. Approved Blue Hand educational materials provide a different, often continuing risk-minimization resource.

These forms should not be mixed with promotional campaigns. Safety information must be deliverable through the appropriate channels independently of marketing consent. The particular distribution needs coordination with responsible functions and the agreed communication plan.

Which information matters most?

Recipients should quickly understand the medicine and use affected, what has changed and what action is required. Date, sender and access to further information or the authoritative document version also matter.

Summaries must retain the qualifications relevant to action. A linked letter should be clearly identified by active substance, date and safety issue. This helps avoid confusion with an older or unrelated communication.

What should companies consider when providing it?

Pharmacovigilance, Medical, Regulatory Affairs and communication teams need coordinated processes. Existing materials, training and relevant website pages require assessment against the safety change. Published copies and downloads need version management.

The BfArM collection covers products within its responsibilities; other products may fall particularly within the Paul-Ehrlich-Institut's remit. Accessing a safety letter does not prove that the recommended action has been implemented.

Conclusion: Prioritize clear safety information and implementation

The Rote-Hand-Brief serves risk communication. Actionable instructions, a current document version and reliable delivery to intended recipients are essential. Success should be assessed against its safety purpose rather than reach or brand impact.

Related topics

  • Summary of Product Characteristics (SPC)
  • Package leaflet (PIL)
  • Blue Hand Educational Materials

Only a few physicians log in to your website?

Advertisement

A login that sets a new standard for authenticating HCPs and equips your marketing team with everything they need to successfully promote Rx-products. Learn more on DocID.pro


Stay up to date!

Subscribe to our free Pharma-Marketing-Newsletter.


A Partner For Successful Marketing in Pharma & Healthcare

Advertisement

8awake, the specialized agency for pharma and healthcare marketing, supports you with the successful development and execution of winning campaign activities in healthcare.

Leading providers in pharma and healthcare marketing

Sponsored
  • 8awake
  • MINTT Digital
  • 8awake

    The leading Healthcare & Pharma-Marketing-Agency

  • MINTT Digital

Looking for a new partner in pharma and healthcare marketing?

Visit our agency finder

Copyright 2026 Pharma-Marketing.com.